289 related articles for article (PubMed ID: 12426516)
1. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
2. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Wanwimolruk S; Paine MF; Pusek SN; Watkins PB
Br J Clin Pharmacol; 2002 Dec; 54(6):643-51. PubMed ID: 12492613
[TBL] [Abstract][Full Text] [Related]
3. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
4. Effects of metronidazole on hepatic CYP3A4 activity.
Haas CE; Kaufman DC; DiCenzo RC
Pharmacotherapy; 2001 Oct; 21(10):1192-5. PubMed ID: 11601665
[TBL] [Abstract][Full Text] [Related]
5. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
7. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
8. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
10. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of
Franchetti Y; Nolin TD
J Pharmacol Exp Ther; 2019 Oct; 371(1):151-161. PubMed ID: 31399494
[TBL] [Abstract][Full Text] [Related]
13. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
Watkins PB; Turgeon DK; Saenger P; Lown KS; Kolars JC; Hamilton T; Fishman K; Guzelian PS; Voorhees JJ
Clin Pharmacol Ther; 1992 Sep; 52(3):265-73. PubMed ID: 1526083
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.
Chhun S; Verstuyft C; Rizzo-Padoin N; Simoneau G; Becquemont L; Peretti I; Swaisland A; Wortelboer R; Bergmann JF; Mouly S
Br J Clin Pharmacol; 2009 Aug; 68(2):226-37. PubMed ID: 19694743
[TBL] [Abstract][Full Text] [Related]
15. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
16. Effects of uptake and efflux transporter inhibition on erythromycin breath test results.
Frassetto LA; Poon S; Tsourounis C; Valera C; Benet LZ
Clin Pharmacol Ther; 2007 Jun; 81(6):828-32. PubMed ID: 17361125
[TBL] [Abstract][Full Text] [Related]
17. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
Polk RE; Brophy DF; Israel DS; Patron R; Sadler BM; Chittick GE; Symonds WT; Lou Y; Kristoff D; Stein DS
Antimicrob Agents Chemother; 2001 Feb; 45(2):502-8. PubMed ID: 11158747
[TBL] [Abstract][Full Text] [Related]
19. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation.
Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
Kidney Int; 2005 Mar; 67(3):1152-60. PubMed ID: 15698457
[TBL] [Abstract][Full Text] [Related]
20. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
Evans DC; O'Connor D; Lake BG; Evers R; Allen C; Hargreaves R
Drug Metab Dispos; 2003 Jul; 31(7):861-9. PubMed ID: 12814962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
